Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Metabolon Launches Fourth Generation DiscoveryHD4™ Metabolomics Platform

Published: Saturday, April 05, 2014
Last Updated: Saturday, April 05, 2014
Bookmark and Share
New technology advancements have potential to lead the way to new scientific breakthroughs, novel biomarkers and discoveries, and support diagnostic product pipeline.

Metabolon, Inc. has announced the launch of DiscoveryHD4™, the company’s fourth-generation metabolomics platform.

This new technology platform will empower the company's metabolomics TrueVision™, mVision™ and mView™ research and biomarker discovery offerings, as well as its diagnostic product development pipeline.

Further extending Metabolon's leadership position in metabolomics research and diagnostics, this platform enables a more expansive and precise global biochemical coverage of metabolite markers across the entire metabolome, thus increasing the ability to discover novel biomarkers and research questions.

Two key innovations power the DiscoveryHD4™ platform advancements. First, accurate mass instrumentation coupled to our new software technology provides a profound increase in sensitivity, and leads to the detection of more metabolites with greater precision.

Second adding a hydrophilic interaction chromatography (HILIC) method to the company’s standard platform technology provides a more complete picture for metabolites within central carbon, or “energy,” metabolism, among other advances.

The novel software tools that Metabolon has pioneered leverages these technical advancements. Together with Metabolon’s wealth of biochemistry expertise, these advancements are significant ingredients to Metabolon’s leadership and success in metabolomics.

“This new technology platform advances the evolution of our metabolomics capabilities and intellectual property,” said John Ryals, Ph.D, President and CEO of Metabolon. “These capabilities are a primary reason we are seeing more collaborations with large initiatives such as the one we recently announced with Craig Venter’s new genomics initiative, Human Longevity Inc. There is growing recognition of the value metabolomics offers to empower genomics and connect genetics to the phenotype, or the living system’s observable characteristics. Having a metabolomics technology platform with an industrialized capability and a capacity that can keep pace with the power of modern sequencing technologies is important to maintaining our position of industry leadership. The breadth of metabolome coverage that this new platform now provides enables more mechanistic insight into the basis of human health and disease.”

“Our scientists are ecstatic about the enhanced resolving power that the DiscoveryHD4™ will deliver our clients across academia and the biotechnology industry. We are already leveraging the enhanced resolving power of the new platform to fuel our diagnostic biomarker discovery pipeline,” commented Michael Milburn, Ph.D., Chief Scientific Officer of Metabolon.

Milburn continued, “Not only are we able to identify more metabolite markers than ever before, we have extended our capabilities to routinely measure additional classes such as steroids and energy metabolites. With these advancements, we can take a complex sample, such as blood, and rapidly identify and rigorously quality control up to 1,000 metabolites in a single biological sample, more than many have thought possible. Practically, this means our potential to discover more sensitive and specific biomarkers and understand what these signatures mean for the underlying biology is dramatically heightened.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Global Genomics Group and Metabolon to Collaborate
Metabolon will conduct biochemical profiling in single largest prospective pan-omic study.
Thursday, November 14, 2013
Scientific News
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
FNIH Launches Project to Evaluate Biomarkers in Cancer Patients
Company has announced that it has launched a new project to evaluate the effectiveness of liquid biopsies as biomarkers in colorectal cancer patients.
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!